狄诺塞麦大陆有卖吗？

Tumor bone metastasis is a common occurrence in all types of tumors. When cancer cells metastasize to bones, the common symptoms are bone damage and severe pain. Bone metastasis often occurs in the lumbar spine, thoracic spine, femur and other parts. Once bone metastasis in these parts occurs, if it cannot be treated in time or is handled improperly, it will lead to complications, loss of mobility or death. The successful development of (denosumab) has brought a new landmark treatment method to patients with bone metastasis.

So is denosumab (denosumab) available in mainland China?

In June 2010, the FDA approved denosumab (denosumab) for the treatment of osteoporosis in postmenopausal women, and was later approved for the treatment of osteoporosis in men, bone loss caused by androgen deprivation therapy for prostate cancer, and bone loss caused by aromatase inhibitor therapy for breast cancer. In November of the same year, based on the results of three randomized controlled phase III clinical studies, the FDA approved denosumab (denosumab) for the treatment of bone-related events in patients with solid tumor bone metastases, and was later approved for the treatment of giant cell tumor of bone and malignant hypercalcemia. In addition, Amgen is continuing to expand new indications for denosumab (denosumab). For example, in January 2018, the FDA approved denosumab (denosumab) for the treatment of SREs in patients with multiple myeloma. Denosumab also received orphan drug designation for the treatment of giant cell tumor of bone and malignant hypercalcemia.

At the same time, in 2018, denosumab (denosumab) injection was included in the list of overseas new drugs in urgent clinical need (first batch) and entered the rapid review channel of the National Medical Products Administration. This approval makes denosumab (denosumab) the first and currently the only drug approved for the treatment of giant cell tumor of bone.

Although this drug is already on the market in my country, due to various reasons, it is not accessible to ordinary patients. Patients can only buy it in countries and regions where denosumab (denosumab) is already on the market. It is worth mentioning that the price of Amgen’s original drug denosumab (denosumab) in Turkey is the lowest in the world. The specification of Turkey (denosumab) is 120 mg, and the price is equivalent to RMB 1,500. Patients can go abroad in person to purchase medicines. If it is inconvenient to go abroad during the epidemic, they can also choose domestic regular medical service institutions (such as Medical Companion Travel) to obtain them.

Recommended related hot articles: /newsDetail/77881.html